pharma · Juvenile idiopathic arthritis · juvenile idiopathic arthritis
Alfasigma
Alfasigma S.p.A.
Alfasigma S.p.A is a pharma organization headquartered in BOLOGNA, IT. Primary therapeutic focus areas include Juvenile idiopathic arthritis, juvenile idiopathic arthritis, Axial Spondyloarthritis, Ulcerative colitis, Rh
BOLOGNA, IT HQ
2,481 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- BOLOGNA, IT
- Employees
- 2,481
- Programs
- 8
- Drugs
- 8
- Patents
- 25
GLPG0634-CL-331
Phase 3 · small molecule · Ulcerative colitis
GLPG0634-CL-331 for Ulcerative colitis is a Phase 3 program (small_molecule) at Alfasigma S.p.A. with 1 ClinicalTrials.gov record(s).
Internal code GLPG0634-CL-331
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Alfasigma S.p.A.
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Ulcerative colitis
- Status
- active
- Trials
- 1